New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide (Q33826198)

29 July 2017

1 reference

title

New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide (English)

1 reference

29 July 2017

0 references

1 reference

Ravot E

1

1 reference

29 July 2017

Lisziewicz J

series ordinal

2

1 reference

29 July 2017

Lori F

series ordinal

3

1 reference

29 July 2017

publication date

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

58

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

953-963

1 reference

Cyclosporine-induced deterioration in patients with AIDS.

29 July 2017

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Adverse reactions to thalidomide in patients infected with human immunodeficiency virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Novel biological response modifiers derived from thalidomide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

An overview of the clinical experience with hydroxyurea

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Hydroxyurea induced hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Inhibitory effect of papaverine on HIV replication in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Papaverine hydrochloride: effects on HIV replication and T-lymphocyte cell function

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

RENAL ABNORMALITIES INDUCED BY HYDROXYUREA (NSC-32065)

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation--data on four cases and review of the literature.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Gag protein from human immunodeficiency virus type 1 assembles in the absence of cyclophilin A.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Short-term anti-HIV activity of the combination of didanosine and hydroxyurea

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Mechanism of action of hydroxyurea

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Are HIV-specific CTL responses salutary or pathogenic?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Thalidomide inhibits the replication of human immunodeficiency virus type 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Long-term suppression of HIV-1 by hydroxyurea and didanosine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Cellular factors: targets for the treatment of HIV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Thalidomide: rationale for renewed use in immunological disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

A phase I study of hydroxyurea

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Hydroxyurea: mechanisms of HIV-1 inhibition.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

UFT in gastric cancer: current status and future developments.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell Turnover

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Functional association of cyclophilin A with HIV-1 virions

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Transplantation in HIV+ patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

HIV-1 replication is controlled at the level of T cell activation and proviral integration

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Skin changes secondary to hydroxyurea therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10651384

12 December 2020

10.2165/00003495-199958060-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1016258438

0 references

1 reference